Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.

[1]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[2]  P. V. Van Schil,et al.  Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Chella,et al.  Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. , 2019, The oncologist.

[5]  Y. Hosomi,et al.  Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1-positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042. , 2019, Annals of Oncology.

[6]  A. Tafreshi,et al.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[8]  C. Gridelli,et al.  Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Investigators.  Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study , 2018 .

[10]  B. Besse,et al.  Progress in the Management of Advanced Thoracic Malignancies in 2017 , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Gettinger,et al.  Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[14]  F. Blackhall,et al.  MA 10.07 Elderly Lung Cancer Patients on Immunotherapy: Preliminary Results from the ELDERS Study , 2017 .

[15]  J. Jassem,et al.  1303PDNivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status , 2017 .

[16]  K. Rabe,et al.  Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. , 2017, The New England journal of medicine.

[17]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[18]  E. Stepanski,et al.  P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153: Topic: IT , 2017 .

[19]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[20]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[21]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[22]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[24]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[26]  B. Milleron,et al.  Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial , 2011, The Lancet.

[27]  Lesley Seymour,et al.  Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Seymour,et al.  Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.